The global Hexapeptide-10 market was valued at $300 million in 2024 and is expected to grow to $500 million by 2035, with a predicted compound annual growth rate (CAGR) of about 5.9% during the forecast period.
The North American market is expected to maintain its leading position, while Europe remains steady; the Asia-Pacific region is showing strong growth potential due to rising disposable incomes and increased skincare awareness.
